Company intelligence / Profile preview

Arvinas

New Haven, Connecticut, USAarvinas.com ↗

Ownership: Public · ARVN
Development stage: Phase 3

Overview

Arvinas is advancing several clinical-stage programs, including bavdegalutamide (ARV-110) and ARV-766 for prostate cancer, and ARV-471 for breast cancer.

Therapeutic areas: OncologyNeurology
Modalities: PROTAC protein degraders
Industry: Biotech

Drug pipeline

13 assets

vepdegestrant

Approved

12 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with pharmaceutical companies for advancing protein degradation technology

Financials

Market cap: $585.9M
Total revenue: $249.7M
Enterprise value: $26.2M

Beyond the preview

Go deeper on Arvinas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arvinas.

Explore the full profile